Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway
What this study shows
Solves the crystal structure of Sestrin2 bound to leucine, revealing the molecular pocket that lets it act as mTORC1's dedicated leucine sensor.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human cell lines (crystal structure)) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Human cell lines (crystal structure) |
| Journal | Science |
| Year | 2015 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1126/science.aad2087 · PMID 26586190 · Free full text (PMC4698039) |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Structural (crystal structure of Sestrin2-leucine) |
| Target | Sestrin2 / leucine / GATOR2 / mTORC1 |
| Model | Human cell lines (crystal structure) |
| Effect | Structure of Sestrin2 bound to leucine reveals the leucine-sensing mechanism for the mTORC1 pathway |
In the Atlas
Related topics
Links in the pathway map
- Supports Leucine inhibits Sestrin2
Open questions that cite this study
- Cited as supporting evidence for the open question Sensor-selective geroprotection without the metabolic penalty.
More studies on this topic
- Dynamics of mTORC1 activation in response to amino acids (2016)
- D-Amino Acid Prodrug DLMEH Activates mTORC1 via Sestrin2 to Restore Muscle Protein Synthesis in Sarcopenia. (2026)
- p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling (2008)
- ATF4 activates a transcriptional program that chronically suppresses mTOR activity and promotes neurodegeneration in Parkinson disease models (2026)
Was this page useful?
Thank you. Your answer was counted anonymously.